San Francisco Chronicle

First malaria vaccine tried out in babies in 3 nations

- By Cara Anna and Lauran Neergaard Cara Anna and Lauran Neergaard are Associated Press writers.

TOMALI, Malawi — A pinch in the leg, a squeal and a trickle of tears. One baby after another in Malawi is getting the first and only vaccine against malaria, one of history’s deadliest and most stubborn diseases.

The southern African nation is rolling out the shots in an unusual pilot program along with Kenya and Ghana. Unlike establishe­d vaccines that offer nearcomple­te protection, this new one is only about 40% effective. But experts say it’s worth a try as progress against malaria stalls: Resistance to treatment is growing and the global drop in cases has leveled off.

With the vaccine, the hope is to help small children through the most dangerous period of their lives. Spread by mosquito bites, malaria kills more than 400,000 people every year, twothirds of them under 5 and most in Africa.

Sevenmonth­old Charity Nangware received a shot on a rainy December day at a health clinic in the town of Migowi.

She watched curiously as the needle slid into her thigh, then twisted up her face with a howl.

“I’m very excited about this,” said her mother, Esther Gonjani, who herself gets malaria’s aches, chills and fever at least once a year and loses a week of field work when one of her children is ill.

There is little escaping malaria during the fivemonth rainy season. Stagnant puddles, where mosquitoes breed, surround the homes of brick and thatch and line the dirt roads through tea plantation­s or fields of maize and sugar cane.

It took three decades of research to develop the new vaccine, which works against the most common and deadly of the five parasite species that cause malaria. The parasite’s complex life cycle is a huge challenge. It changes forms in different stages of infection and is far harder to target than germs.

“We don’t have any vaccines against parasites in routine use. This is uncharted territory,” said Ashley Birkett, who directs PATH’s Malaria Vaccine Initiative, a nonprofit that helped drugmaker GlaxoSmith­Kline develop the shot, brandnamed Mosquirix.

The bite of an infected mosquito sends immature parasites called sporozoite­s into the bloodstrea­m. If they reach the liver, they’ll mature and multiply before spewing back into the blood to cause malaria’s debilitati­ng symptoms. At that point, treatment requires medicines that kill the parasites.

Newspapers in English

Newspapers from United States